NEW YORK (GenomeWeb) – Abbott reported on Wednesday that its fourth quarter diagnostic revenues grew 3 percent year over year, despite an unfavorable 1 percent effect from foreign exchange.

Its molecular diagnostics revenues dropped 8 percent driven by a planned scale down of its genetics business that offset growth in infectious disease testing.